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Summary 
We have previously reported that ES-62, a molecule secreted by the parasitic filarial nematode 
Acanthocheilonema viteae, protects mice from developing collagen-induced arthritis (CIA). 
Together with increasing evidence that worm infection may protect against autoimmune 
conditions, this raises the possibility that ES-62 may have therapeutic potential in Rheumatoid 
Arthritis and hence, it is important to fully understand its mechanism of action.  Towards this, 
we have established to date that ES-62 protection in CIA is associated with suppressed 
Th1/Th17 responses, reduced collagen-specific IgG2a antibodies and increased IL-10 
production by splenocytes. IL-10-producing regulatory B cells (Bregs) have been proposed to 
suppress pathogenic Th1/Th17 responses in CIA: interestingly therefore, whilst the levels of IL-
10-producing B cells were decreased in the spleens of mice with CIA, ES-62 was found to 
restore these to the levels found in naive mice. In addition, exposure to ES-62 decreased effector 
B cell, particularly plasma cell, infiltration of the joints, and such infiltrating B cells showed 
dramatically reduced levels of TLR4 and the activation markers, CD80 and CD86. Collectively, 
this induction of hyporesponsiveness of effector B cell responses, in the context of the resetting 
of the levels of IL-10-producing B cells, is suggestive of a modulation of the balance between 
effector and regulatory B cell responses that may contribute to ES-62-mediated suppression of 
CIA-associated inflammation and inhibition of production of pathogenic collagen-specific 
IgG2a antibodies.  
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Introduction 
 
The prevalence of autoimmune disease in the developing world inversely correlates with 
parasitic helminth infection1, 2, an apparent serendipitous side-effect of the ability of worms to 
secrete anti-inflammatory molecules that modulate the host immune system and promote 
parasite survival. Such epidemiological evidence has understandably generated interest in the 
therapeutic potential of such immunomodulators and also in their use as tools to dissect the 
pathogenic mechanisms underlying inflammatory disorders3. We have previously shown that 
one such immunomodulator, ES-62, a phosphorylcholine (PC)-containing glycoprotein, 
secreted by the filarial nematode Acanthocheilonema viteae, is protective in the mouse collagen-
induced arthritis (CIA) model of Rheumatoid Arthritis (RA) by acting to suppress pathogenic 
Th1/Th17 responses 4. The success of rituximab as a therapy for autoimmune disease has 
refocused interest on the pathogenic and protective roles of B cells in RA5 with recent studies 
highlighting the importance of IL-10-producing regulatory B cells (Bregs) in the prevention and 
amelioration of CIA and also antigen-induced arthritis (AIA), via the suppression of Th1/Th17 
responses and the promotion of Tr1 and Treg differentiation5-8. Interestingly, therefore, we have 
found that whilst exposure to ES-62 results in enhanced spontaneous ex vivo production of IL-
10 by splenocytes from mice with CIA, it induces hyporesponsiveness of normal and CIA-
derived splenic B cells and reduces the levels of pathogenic collagen-specific IgG2a antibodies9. 
Relating to this, we now show that the protective effects of ES-62 in CIA are associated with 
restoration of the levels of IL-10-producing B cells and suppression of infiltration of activated 
plasma cells into the joints, perhaps suggesting that ES-62 may act, at least in part, to modulate 
the balance between effector and regulatory B cell responses in this mouse model of RA.  
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Materials and Methods  
CIA 
Animals were maintained in the Biological Services Units in accordance with the Home Office 
UK Licences PPL60/3580, PPL60/3791, PPL60/4300 and PIL60/9576, PIL60/12183 and 
PIL60/12950 and the Ethics Review Boards of the Universities of Glasgow and Strathclyde. 
CIA was induced in male DBA/1 mice (8-10 weeks old; Harlan Olac; Bicester, UK) by 
intradermal immunization with bovine type II collagen (CII, MD Biosciences) in complete 
Freund’s adjuvant (FCA) on day 0 and in PBS on day 21. Mice with CIA were treated with 
purified endotoxin-free ES-62 (2 µg/dose) or PBS subcutaneously on days -2, 0 and 21 and cells 
were recovered from joints 10 as previously described 4, 9, 11. All analysis was performed at cull 
(day 28) and represents data from at least 2 independent experiments.    
 
Ex vivo analysis  
Splenocytes and draining lymph node (DLN) cells (106/ml) were analysed for B cell IL-10 
responses by stimulating ± 50 ng/ml PMA (Sigma-Aldrich, UK) plus 500 ng/ml ionomycin 
(Sigma-Aldrich, UK) and 10 µg/ml LPS (E. coli O111:B4, Sigma-Aldrich, UK) for 1 h before 
addition of 10 μg/ml Brefeldin A (Sigma-Aldrich, UK) for 5 h at 37oC with 5 % CO212, 13. 
Lymphocyte subsets were analysed by flow cytometry of unstimulated cells adapting the gating 
strategy (Fig. 1) of Allman & Pillai14 using antibodies specific for the following markers (with 
relevant fluorochrome): CD5/Biotin-svE450; CD8/Biotin-svPerCP (both BD Pharmingen, NJ, 
USA); AA4.1/APC; B220/BV421; CD11c/Biotin-svPerCP; CD138/PE; CD19/AF700; 
CD1d/PE; CD23/PE-Cy7; CD24/PerCP-Cy5.5; CD4/Biotin-svPerCP; CD43/PE-Cy7; 
IgD/PerCP-Cy5.5; IgM/APC-Cy7; F4/80/Biotin-svPerCP (all BioLegend, CA, USA), 
CD21/E450 and GL7/E450 (both eBioscience, CA, USA). Additional phenotypic markers were 
labelled using anti-TLR4-APC (R&D Systems, UK), anti-BAFF-R-FITC (eBiosciences), anti-
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CD4-PE, anti-CD80-PerCP/Cy5.5 or anti-CD86-AF488 (BioLegend) antibodies before the cells 
were fixed and permeabilised using BioLegend products and protocols.  Stimulated cells were 
then labelled using anti-IL-10-APC (BioLegend) antibodies for 30 min prior to flow cytometry 
to detect IL-10-producing B cells. Data analysis gates were set according to appropriate isotype 
controls. Dead cells were identified and excluded from analysis using the Live/Dead® Fixable 
Dead Cell Stain (Aqua) using manufacturers suggested protocol (Invitrogen).  
 
Statistics  
Parametric data were analysed by the Student's t test or by 1-way ANOVA whilst non-
parametric data were analysed by Mann Whitney and Kruskal-Wallis tests where *p<0.05, 
**p<0.01 and ***p<0.001. 
 
Results 
ES-62 reduces the levels of Germinal Centre B cells in the spleens of mice with CIA   We 
investigated whether ES-62-mediated protection against CIA (Fig. 2A) correlated with 
modulation of B cell populations (Fig. 1). There was no significant modulation by the helminth 
product of either the proportion or number of CD19+ B cells in the spleen (Fig. 2B; numbers 
(x106) ± SEM: Naive, 25.13 ± 2.26; PBS, 26.86 ± 1.76; ES-62, 28.27 ± 2.68) or LN (data not 
shown) and consistent with this, no significant changes were observed in the transitional (T1-
T3), marginal zone precursor (MZP) or marginal zone (MZ) populations in the spleen (Fig. 2C 
& D and results not shown). However, ES-62 significantly increased the levels of 
CD19+CD21lowCD23high Follicular B cells (Fo; Fig. 2C & D) and further analysis showed that 
whilst exposure to ES-62 had no effect on follicular type-2 (Fo2) B cells (results not shown), it 
significantly increased the levels of Follicular type-1 B2 cells (Fo1; Fig. 2E; numbers (x106) ± 
SEM: Naïve, 5.58 ± 0.82; PBS, 6.08 ± 0.64; ES-62, 7.97 ± 0.91) in the spleen. The increase in 
Fo1 B cells was associated with corresponding reductions in germinal centre B cells (GC; Fig. 
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2F; numbers (x106) ± SEM are: PBS, 6.28 ± 1.36; ES-62, 2.95 ± 0.39) and 
CD3+CD4+ICOS+CXCR5+ follicular helper T cells (TFH; from 2.42 (PBS) to 1.49% of live 
splenocytes exposed to ES-62) in the spleen. By contrast, ES-62 had no effect on the levels of 
CD19+B220+IgM-IgD-IgG+ cells, which may represent a subset of memory B cells (results not 
shown). Collectively, these data suggest that ES-62 may act to reduce the generation of 
pathogenic antibodies by blocking the activation of follicular B cells and their consequent 
differentiation into GC B cells15. 
 
ES-62 modulates the recruitment of B cells to the joints of mice with CIA 
As pathogenic B cells migrate to the joints and even form ectopic germinal centres in response 
to B cell recruitment and survival factors such as BAFF, CXCL12 and CXCL13 secreted by 
synovial fibroblasts 5, we next analysed whether the above effects of in vivo exposure to ES-62 
on the profile of B cells were reflected in the arthritic joint. This revealed that both the 
proportion (Fig. 3A&B) and absolute numbers (Fig. 3C) of CD19+ B cells found in the joints 
were significantly reduced by ES-62 treatment. This reduction was reflected in a CD19+CD23+ 
B cell population (Fig. 3D&E), which further analysis revealed to be follicular type 1 B cells 
(Table 1). There was also a clear decrease in CD19-CD138+ (from 9.27 to 2.45% live cells) and 
CD19+CD138+ (from 15.6 to 4.51% live cells) cells infiltrating the joints of mice treated with 
ES-62 (Fig. 3F&G) suggestive of a reduction in plasma cells.  Consistent with this, further 
analysis, excluding the myeloid and T cell lineages expressing CD138 (Fig. 3H), revealed that 
exposure to ES-62 indeed suppressed the proportions  (Fig. 3I-J) and numbers (Table 1) of 
CD19-B220-CD138+ (from 8.31 to 3.69% live cells) and CD19+B220low/-CD138+ (from 1.37 to 
0.72% live cells) plasma cells, which respectively are phenotypically similar to the long-lived 
plasma cell and short-lived plasma cell/plasmablast functional populations, reported 
previously16-18.  This presumably reflects reduced development and/or migration of such cells, 
as suggested by the significant increases in the levels of Fo1 (Fig. 2E) and CD19-B220-CD138+ 
plasma cells (numbers (x106) ± SEM: Naïve, 0.75 ± 0.22; PBS, 1.28± 0.31; ES-62, 1.58± 0.26) 
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found in the spleen, since ES-62 did not modulate the levels of early CD19+B220+CD138+ "pre-
plasma cells" which have been reported as being subject to a tolerance checkpoint that is 
defective in the autoimmune-prone MRL/Lpr mouse19 (results not shown). 
In addition to investigation of modulation of the levels of B cells found in the joint, ES-
62 was assessed for effects on the functional phenotype of such infiltrating cells. Thus, whilst 
ES-62 did not significantly modulate the expression of BAFF-R, CD80, CD86 or TLR4 (either 
in terms of percentage positive cells or levels of expression) on splenic CD19+ B cells, 
expression of CD80, TLR4 and, to a lesser extent, CD86, but not BAFF-R, by CD19+ B cells in 
the joint was down-regulated, mirroring a tendency towards a decrease in expression of both 
CD80 and TLR4 by CD19+ DLN cells (Results not shown).  Further analysis revealed that this 
reflected selective downregulation of TLR4, CD80 and CD86 expression on 
CD19+CD23highCD21low follicular B cells but not CD19+CD23-CD21high or 
CD19+CD23highCD21high B cells (Fig. 4 and results not shown). Moreover, although B1, GC and 
plasma cells also expressed TLR4, such expression was not modulated by exposure to ES-62 
(results not shown).  
Collectively, therefore, these data suggest that ES-62 may act to prevent development and 
migration of pathogenic B cells to the site of inflammation, with the residual B cells that 
infiltrate the joint being rendered functionally hyporesponsive.  
 
ES-62 restores the levels of IL-10-producing B cells in the spleen of mice with CIA 
IL-10 producing B cells that exhibit regulatory activity (Bregs) have been reported to curb 
pathogenic Th1/Th17 responses in CIA and it has been proposed that these cells protect against 
disease by promoting the development of Tr-1 regulatory T cells6. Although the ES-62-
mediated suppression of B cell development and migration (Fig. 2&3) and consequent 
inhibition of generation of pathogenic IgG2a responses observed in CIA11 might reflect the 
ability of the parasitic worm product to induce hyporesponsiveness of B2 cells by uncoupling 
the BCR from ErkMAPkinase signalling, both in vitro and in vivo 20, 21, it is also interesting to 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
note that ES-62 has previously been shown to induce the production of IL-10 by peritoneal B1 
B cells22. As B1 cells are not thought to play a central role in systemic autoimmunity and 
autoantibody production in CIA23, it is therefore possible that the reduced levels of 
CD19+IgM+CD43highCD5+ and CD19+IgM+CD43highCD5- cells, that have been reported to be 
B1a and B1b cells respectively24-28, found in the spleens (Fig. 5A-C) and DLNs (Fig. 5D) of ES-
62-treated mice with CIA could reflect their egress and migration to the joints to mediate IL-10-
dependent anti-inflammatory effects. Perhaps consistent with this, although the levels of B cells 
infiltrating the joint overall were reduced following treatment with ES-62, the proportion of 
such B1-like cells was slightly increased (PBS: 1.42%, 1.3%; ES-62: 1.58%, 1.51%, where data 
are expressed as the proportion (%) of live cells, that are CD43+CD19+IgM+ B1-like cells, 
harvested from the joints of 6-7 mice/group in 2 independent experiments).   
 
Analysis of IL-10-producing B cells (Fig. 6A&B) revealed that whilst induction of CIA resulted 
in a significant reduction in the levels of IL-10-producing B cells, relative to naïve mice, this 
was not the case for those treated with ES-62 (Fig. 6C). Indeed, exposure to ES-62 led to a 
significant enhancement in the level of IL-10-producing B cells in mice with CIA, restoring 
them to levels comparable with those found in healthy naive mice (Fig. 6C; numbers (x106) ± 
SEM: Naïve, 1.81 ± 0.22; PBS, 1.48 ± 0.12; ES-62, 1.99 ± 0.26). CD19+IL-10+ B cells in the 
spleens of naïve and CIA mice reflected a mixed population comprising phenotypes consistent 
with marginal zone precursor, marginal zone, follicular B cells and CD19+CD21-CD23- B cells 
(Fig. 6B): almost all of these cells expressed CD1d whilst some 20-30% of the follicular and 
CD19+CD21-CD23- B cells expressed CD5 (data not shown), the latter a marker previously 
associated with certain IL-10-producing B cells 29, 30. Rather surprisingly, the ability of ES-62 to 
return the levels of IL-10-producing B cells towards that existing in naïve, non-arthritic mice, 
did not appear to involve a preferential modulation of any of these phenotypes perhaps 
suggesting that it acts rather to regulate B cell responses in a  "homeostatic" manner. Although 
the protective effects of IL-10-producing B cells in CIA have previously been reported to be 
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associated with the induction of Tr-1 regulatory cells 6, our analysis showed the IL-10 
production by splenocytes to be predominantly B cell-derived (Fig. 6A) and that the CD19-IL-
10+ population was not increased by treatment with ES-62 (Fig. 6D), suggesting that Tr-1 cells 
were not being induced in this case.  Likewise, and consistent with the previously reported lack 
of Breg-mediated induction of Tregs in the CIA model6, further investigation indicated that in 
vivo treatment with ES-62 did not result in enhanced levels of FoxP3-expressing CD4+ 
regulatory T cells in the DLN (results not shown), as shown following induction of Bregs in 
AIA31.  
 
Discussion 
The successful clinical implementation of B cell-depletion therapies in recent years has 
reignited interest in the pathogenic and protective roles of B cells in RA. In particular, much 
interest has focused on the ability of IL-10-producing regulatory B cells to prevent development 
of pathogenic Th1/Th17 responses and induce regulatory T cells that result in the suppression of 
disease in the antigen (methylated BSA)-induced arthritis  (AIA) and CIA mouse models of 
RA6, 8, 31. Interestingly, therefore it has recently emerged that one of the strategies exploited by 
parasitic helminths to dampen host immune responses and hence promote their survival is the 
induction of IL-10-producing Bregs: moreover, the protection afforded against allergic 
inflammatory disease by such worms has also been associated, at least in part, by their induction 
of such Bregs28, 32-35. Thus, our current findings that exposure to ES-62 results in elevated levels 
of IL-10-producing B cells may provide a rationale for our previous findings that the parasite 
product exerts its protective effects in CIA via suppression of Th1, Th17 and IL-17-producing 
γδ T cell responses, as well as being consistent with our earlier observation that it promotes 
spontaneous IL-10 production by splenocytes from mice with CIA4, 9, 11. Interestingly, although 
regulatory B cells have been proposed to mediate at least some of their protective effects in 
experimental arthritis via the generation of natural Tregs (AIA) and/or induced Tr1 (AIA and 
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CIA) cells6, 8, 31, we have found no evidence that ES-62 induces any IL-10-producing regulatory 
T cells in DBA/1 mice with CIA. Although perhaps surprising, this failure to induce Tregs is 
supported by our preliminary data from the C57BL/6 model of chronic CIA36, in which in vivo 
exposure to ES-62 does not increase the levels of either FoxP3+ or IL-10-producing CD4+ T 
cells in the DLN of such mice (results not shown) and is consistent with their lack of induction 
in our previous studies investigating ES-62-mediated hyporesponsiveness to the model antigen 
Ovalbumin (OVA) in both the DO.11.10 transfer model37 and the OVA-induced airway 
inflammation model38 of asthma. Nevertheless, we cannot rule out the possibility that whilst ES-
62 does not increase the levels of Tregs in mice with CIA, it may act to reverse/overcome the 
impaired (cell contact-mediated) suppressive ability of Tregs reported in RA39.  
 
Perhaps also surprisingly, the restoration of IL-10-producing B cells resulting from exposure to 
ES-62 did not reflect induction of a particular phenotype of B cells associated with regulatory 
function: although modest, these statistically significant increases in IL-10-producing B cells 
are consistent with the numbers seen in other studies in the absence of enrichment by anti-CD40 
or LPS/IL-21 stimulation12, 40, 41 and suggest that ES-62 may be acting in a homeostatic manner 
to reset the balance of effector and regulatory B cells back towards that observed in healthy 
DBA/1 mice.  However, whilst the ES-62-mediated suppression of the level of GC B cells was 
associated with a reduction of Tfh cells, our preliminary data suggest that the residual Tfh cells 
produced slightly higher levels of the cytokine, IL-21 that appears to be critical for the 
generation of functional Bregs that combat autoimmunity41.  Thus, as we have not formally 
demonstrated regulatory function of these IL-10 producing B cells, we cannot rule out the 
possibility at this stage that ES-62 is also reversing the defective regulatory function of one or 
more Breg phenotypes observed in CIA and also in RA patients42, 43.  Nevertheless, we have 
shown previously that whilst ES-62 induces high levels of IgG1, but not IgG2a, antibodies in 
naive wild type BALB/c mice, in IL-10-/- mice the helminth product induces both IgG1 and 
IgG2a antibodies. This suggests that IL-10 plays an important role in the suppression of IgG2a 
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antibodies directed against ES-6244. Interestingly, therefore, we have shown that neither the ES-
62-mediated suppression of DC-priming of OVA-specific Th1 responses45 nor the suppression 
of TLR-mediated IL-12 responses of macrophages exposed to ES-62 either in vitro or in vivo46 
is due to autocrine production of IL-10 by APC. By contrast, whilst we have shown that 
exposure to ES-62 in vivo induces hyporesponsiveness of splenic B2 cells, peritoneal B cells 
from such mice produced enhanced spontaneous and BCR-stimulated IL-10 responses21, 22 and 
although these peritoneal cells will predominantly comprise B1 cells, there is increasing 
evidence that they likely also include some B2 cells 27.  
 
Collectively, therefore, these data suggest that exposure to ES-62 leads to hyporesponsiveness 
of effector B2 cell responses and restoration of IL-10-producing B cells that in CIA, given the 
complex interplay between B cell-derived IL-10 and pathogenic IL-17 responses in the 
regulation of inflammation and autoantibody responses 6, 12, 31, 41, 47-49, results in the reduction of 
plasma cells that may contribute to the suppression of pathogenic autoantibodies and 
inflammation associated with the protection against CIA. For example, the ability of B cell-
derived IL-10 to impact on APC such as DC in vivo may contribute to the effects of ES-62 on 
the DC-dependent priming of Th1/Th17 and IL-17-producing γδ T cells 4, 38, 45. Alternatively, 
such IL-10 may suppress effector B cell activation with consequent induction of T cell 
hyporesponsiveness, as the reduction of GC B cells and TFH cells observed in the spleens of ES-
62-treated mice is reminiscent of that reported for mast cell-derived IL-10-mediated suppression 
of TFH cell function 50. This could be particularly important at the site of inflammation with the 
profound downregulation of CD80 and CD86 expression on follicular B cells impacting on the 
functionality of ectopic GCs given that expression of CD80 by B cells has been shown to be 
important in the regulation of Tfh development, and consequent GC B cell survival and plasma 
cell production51, the latter population being clearly reduced in the joints of ES-62-treated mice. 
Interestingly therefore, blocking of B7-CD28 interactions has been reported to be sufficient to 
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prevent development of CIA52.  Finally, the strong downregulation of TLR4 is similarly likely 
to suppress B cell activation and plasma cell generation at this site 53, and in this way, disrupt 
the destructive chronic inflammation resulting from cells in the joint expressing upregulated 
levels of TLRs, including TLR454 and responding to DAMPs,  such as HSP22 and tenascin-C 55 
found in the synovium of RA patients. 
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Table 1: Exposure to ES-62 in vivo suppresses infiltration of the joints by B2 cells and 
plasma cells.  
 
Group CD19+B220low/-CD138+  CD19-B220-CD138+ Fo1 
Exp 1 2 1 2 1 2 
PBS 0.24 0.67 1.5 0.74 0.029 0.11 
ES-62 0.035 0.32 0.18 0.36 0.009 0.033 
 
Data (number of cells x 106) are presented from 2 independent experiments where 
CD19+B220low/-CD138+ and CD19-B220-CD138+ plasma cell and CD19+CD21lowCD23+AA4.1-
IgMlowIgDhigh Fol B cell populations infiltrating the joints were analysed by flow cytometric 
analysis of joint cells harvested from 6-7 mice from each group. 
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Figure Legends  
Figure 1: Gating strategy for analysis of B cell subsets and phenotyping of populations. 
This is a modification of that based on the peripheral B cell phenotypic markers defined by 
Allman and Pillai14. T1: CD19+CD93+CD21intCD23-IgDlow/- IgMhigh; T2: 
CD19+CD93+CD21intCD23+IgDhighIgMhigh; T3: CD19+CD93+CD21int CD23+IgDhighIgMlow; 
MZP: CD19+CD93-CD21highCD23+CD1dhighIgDhighIgMhigh; MZ: CD19+CD93-CD21highCD23-
CD1dhighIgDlow/-IgMhigh; Fo1: CD19+CD93-CD21low CD23+IgDhighIgMlow; Fo2: CD19+CD93-
CD21lowCD23+IgDhighIgMhigh; GC: CD19+ CD43-CD24+GL7+. Cell populations were initially 
selected on the basis of "Lymphocyte" size (forward scatter; FSC) and granularity (side scatter; 
SSC) parameters and excluding "doublets" (by comparing FSC-Height and FSC-Area) and dead 
cells (by the Live/Dead® fixable aqua dead cell dye; Invitrogen) (data not shown). We initially 
gated on CD19+CD23- and CD19+CD23+ cells (A) to resolve MZP (CD21highCD1dhigh) from Fo 
(CD21lowCD1dlow) B cells (B) and MZ (CD21+IgM+) and T1 (CD21-IgM+) cells (C), 
respectively. The follicular (Fo) population identified (B; CD21lowCD1dlow) is a heterogenous 
population that contains the functionally distinct follicular type 1 (Fo1: IgDhighIgMlowAA4.1-) 
and follicular type 2 (Fo2: IgDhighIgMhighAA4.1-) as well as the transitional 2 (T2: 
IgDhighIgMhighAA4.1+) and transitional 3 (T3: IgDhighIgMlowAA4.1+) populations. These 
populations are first separated on the basis of their expression of IgM and IgD (D) and then, 
AA4.1 (E & F). For the identification of germinal centre (GC) B cells we first identify 
CD19+CD43- cells (G) and then exclude contaminating non-B cells by gating on the GC cell 
specific marker GL7 along with the pan B cell marker CD24 (H) before confirming expression 
of FAS (I) by essentially all (>90%) CD19+CD43-CD24+GL7+ GC B cells; we have therefore 
not included this redundant marker in our analysis.  
Figure 2: ES-62 reduces the levels of Germinal Centre B cells in the spleens of mice with 
CIA. Mean articular scores (± SEM) of CIA mice treated with PBS (n=34) or ES-62 (n=18) at 
time of cull at day 28 (A). The percentage of CD19+ B cells (B); representative plots (C) and 
proportions (D; mean values ± SEM of individual mice where naive, n=16; PBS, n= 31; ES-62, 
n=12 ) of MZP, MZ and Fo B cells as defined by their expression of CD21 and CD23; 
Follicular type 1 B cells (Fo1, E: CD19+CD23+CD21lowCD1dlowIgMlowIgDhighAA4.1-) and 
germinal centre (GC; F: CD19+CD43-CD24+GL7+), as derived by the gating strategy in 
presented in Fig. 1, in spleens from mice undergoing CIA are shown.  
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Figure 3: ES-62 modulates the recruitment of B cells to the joints of mice with CIA. Cells 
extracted from the joints of mice with CIA were analysed for the proportion (A & B) and 
number (C) of infiltrating CD19+ B cells (A-C; data in C are presented as the means ± SEM of 4 
biological replicates pooled from two independent experiments) and consequently for the 
relative proportions of CD19+CD23+ (D & E); plasma cells on the basis of CD19 CD138 
expression (F & G). Exclusion of myeloid and T cell-expressing CD138 cells by use of Dump 
channel (CD4+CD8+GR1+F4/80+CD11b+ CD11c +; H) allowed analysis of Dump-CD19-B220-
Cd138+ and Dump-CD19+B220low/-CD138+ plasma cells (I & J). 
Figure 4: ES-62 modulates expression of TLR4 and costimulatory molecules on Follicular 
B cells. CD80, CD86, TLR4 and BAFF-R expression by CD19+CD23highCD21low Follicular B 
cells in the joints of PBS and ES-62 treated mice are presented as expression levels relative to 
isotype control (grey area), for CIA mice treated with ES-62 (broken line) or PBS (black line).  
Cells from at least 5 mice/group were pooled.  
Figure 5: ES-62 modulates the levels of B1-like cells in the spleen of mice with CIA.   
There is no unambiguous phenotype for B1 cells in the spleen but they have been described as 
CD19highCD23-CD43+IgMhighIgDlow/-CD5± cells where CD5+ B1a and CD5- B1b comprise ~2% 
and 1% of cells in the spleen respectively24. However, following gating on CD19+IgM+(A), 
analysis of CD43+CD5± cells has been widely used to describe B1 cells 25, 26 whilst CD19+CD5+ 
gating has been used to describe B1a cells 28. Moreover, whilst CD43 can be upregulated on B2 
cells, this is usually expressed at a lower level than on B1 cells27 and we have thus chosen to 
gate only on CD43high cells (B) in order to exclude any potential CD43+ B2 cells.  We have 
therefore phenotyped CD19highCD43+IgMhighIgD- B cells as CD5+ B1a-like cells and CD5- B1b-
like cells and the data show their relative proportions in the spleen (C; naïve, n=10; PBS, n=13 
and ES-62, n=11) and DLN (D; naïve, n=4; PBS, n=8 and ES-62, n=8) of the indicated groups 
of mice. 
Figure 6: ES-62 induces IL-10-producing B cells in the spleen of mice with CIA. IL-10-
producing CD19+ B cell (A & C) and IL-10-producing CD19-  non-B cell subsets (A & D) in the 
spleen were analysed with the proportions of these cells, in spleens of individual naive mice and 
PBS- and ES-62-treated mice with CIA respectively.  Representative plots of the phenotypes of 
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CD19+IL-10+ B cells based on their expression of CD21CD23 (B) are shown for spleens of 
mice with CIA.  
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